Company intelligence / Profile preview
OncoVerity
Aurora, Colorado, United Statesoncoverity.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
OncoVerity is developing cusatuzumab, a first-in-class anti-CD70 antibody that has shown promising results in early AML studies. The company uses computational biology and single-cell analysis to identify patients most likely to benefit from treatment.
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibody
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
argenxUCHealthUniversity of Colorado Anschutz Medical Campus
Beyond the preview
Go deeper on OncoVerity.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OncoVerity.